Q2 2020

Filed Aug 10, 2020 · 10-Q · 41 days after period end · 0001104659-20-092706

Q2 2020 · 10-Q

Revenue

$466.79K

— vs Q2 2019

Net Income

-$6.34M

N/M vs Q2 2019

EPS Diluted

-$0.14

N/M vs Q2 2019

Operating Income-$6,357,556N/M

Operating Cash Flow

Same quarter

Metric	Q2 2020	Q2 2019	Q2 2018	Q2 2017
Revenue	$466.79K	$0.00	$205.99K	$0.00
Net Income	-$6.34M	-$5.57M	-$4.81M	-$1.89M
EPS Diluted	-$0.14	-$0.12	-$0.41	-$0.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR